Altitude sickness: a small trial of active vitamin D suggests a benefit that needs confirmation

Could active vitamin D ease altitude sickness? A trial in 48 volunteers ascending to 4,200 meters reports less severe symptoms with 1,25-dihydroxyvitamin D3 than with a placebo. But only the abstract is available in the dossier: the size of the benefit and safety remain too poorly documented to support a recommendation.

High-mountain landscape illustrating exposure to low oxygen at altitude.
SupplementsEditorial illustration, not study data.

A short human trial alongside an animal experiment

The study combines a clinical trial, indexed as randomized, with an experiment in rats. In the human trial, 23 volunteers received 1,25-dihydroxyvitamin D3, the active form of vitamin D, and 25 received a placebo for five days, in the context of an ascent to 4,200 meters.

The abstract reports a reduction in the Lake Louise score, used to assess symptoms of acute mountain sickness, as well as fewer headaches. It also mentions improvements in oxygen saturation and hemodynamic parameters.

These results represent an interesting clinical signal. However, the abstract provides neither numerical differences between groups nor uncertainty intervals. This document alone cannot establish whether the improvement meant substantial or modest relief for participants.

A mechanism explored mainly in rats

The animal experiment involved 40 rats exposed for 48 hours to hypobaric hypoxia equivalent to an altitude of 6,000 meters. The researchers describe changes in the Th1/Th2 immune balance, reduced oxidative stress and changes in several metabolites associated with butyrate metabolism.

These observations suggest possible biological links between active vitamin D, inflammation and the response to low oxygen. They do not demonstrate that these mechanisms explain the improvement in symptoms among the volunteers. Nor does the abstract allow every inflammatory or organ-related finding to be confidently attributed to the human trial.

This abstract does not establish safety

The authors present the molecule as a safe and promising preventive option. That wording goes beyond what the excerpt allows us to verify: the reported absence of toxicity concerns controls under normal oxygen conditions, with no detailed account of adverse events among the volunteers.

The small human sample and five-day duration also limit the conclusions. The dossier does not specify exclusion criteria, concurrent treatments, funding or conflicts of interest. Finally, results obtained with this active form cannot be extrapolated to a standard vitamin D supplement.

Limitations to keep in mind

Assessment based solely on the supplied PubMed abstract, without consulting the full text. Small human sample, short follow-up, and no effect sizes or detailed safety data. Funding and conflicts of interest not verified.

What we can take away

This trial suggests a possible benefit for altitude sickness symptoms. It is not enough to recommend active vitamin D for prevention, or to conclude that a standard supplement would produce the same effect.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.